Q2 2019

Filed Aug 8, 2019 · 10-Q · 39 days after period end · 0000886163-19-000156

Q2 2019 · 10-Q

Revenue

$24.99M

−72.2% vs Q2 2018

Net Income

-$14.42M

N/M vs Q2 2018

EPS Diluted

-$0.74

N/M vs Q2 2018

Operating Income-$4,130,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2019	Q2 2018	Q2 2017	Q2 2016
Revenue	$24.99M	$90.04M	$90.04M	$19.52M
Net Income	-$14.42M	$73.16M	$73.16M	-$6.17M
EPS Diluted	-$0.74	$2.99	$2.99	-$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR